

COMPANY PROFILE

Itamar Medical Ltd., established in 1997, is a public medical technology company (TASE: ITAMAR) which developed the proprietary PAT™ (Peripheral Arterial Tone) signal. The PAT signal is a non-invasive "window" to the cardiovascular system and the autonomic nervous system.

Itamar Medical ranks 14th in the Deloitte Fast 50 for 2008, with a five year growth of 1,915%. Deloitte Fast 50 is an annual list of the fastest growing companies in Israel.

PAT: A non-invasive window to the entire body

Today: PAT (Peripheral Arterial Tone) technology is a non-invasive window to the cardiovascular system and autonomic nervous system. Today it is used clinically for detection of Obstructive Sleep Apnea, early detection of heart disease, and erectile dysfunction. PAT-based products provide early-stage detection of disease and facilitate follow-up; improving patient care while reducing the overall cost of healthcare.

Tomorrow: PAT signal technology can also serve as a platform for improving diagnosis and clinical health care in a wide variety of medical conditions such as vascular dementia, diabetes, pre-eclamptic toxemia, metabolic syndrome, renal failure, and peripheral arterial disease to name a few.

Technology: Itamar Medical has developed convenient, easy-to-use, non-invasive proprietary finger probes. The data recorded from the probes is analyzed by advanced digital signal processing algorithms and presented to the physician via dedicated, easy-to-interpret software.

Strong Scientific Basis

Itamar-Medical collaborates with the leading researchers in top medical and research institutes. PAT technology is incorporated in advanced research programs at institutes such as the Framingham Heart Study, The Mayo Clinic, Harvard School of Medicine, Boston University, New England Medical Center, Yale University, Pittsburgh University Medical Center, Mount Sinai NY, Cedars-Sinai, Johns Hopkins University, Emory University and many more. These collaborations have yielded almost 130 peer-reviewed manuscripts and well over 200 abstracts at major scientific meetings.

Intellectual property

The PAT Signal and methodology has a strong intellectual property position. More than 40 patents have been issued in the US, with an additional 28 applications pending. The first allowed US patent claim was very comprehensive and includes the following statement: "Monitoring changes in peripheral arterial tone and determining that a change in the physiological condition of the patient has occurred." Multiple patents were issued worldwide, with several more pending.

The Itamar Standard

Itamar products share the common goal of uniquely designed, single-use PAT finger probes, optimally tailored to measure the PAT signal with application-specific algorithms. The data acquired is automatically processed, analyzed, and presented to the physician by proprietary software. This standard provides for user-independent, highly reliable and reproducible medical devices, facilitating clinician's decision making process and researcher's work in a user-friendly environment necessitating very little training. Itamar Medical's PAT-based devices strategically position the company to meet the diagnosis and consulting needs of busy medical centers and practices in the 21st century.

Publicly traded (TASE:ITMR)

Product lines:

- **WatchPAT™** - Ambulatory Sleep disorder
- **EndoPAT™** - Early detection of cardiovascular disease
- **Pharmaceuticals** - drug development & companion diagnostics

Business indices

- 500,000 patients diagnosed
- 3,500 WatchPATs sold
- 550 EndoPATs sold

Financial indices [Jan 2010]

- Growth: 2009/2008 @ 27%
- Annual run rate ~12m
- Operationally breakeven
- ECB: \$13m
- Market Cap: \$85m

Broad scientific base

- 133 peer-reviewed publications, 200 abstracts

Broad IP coverage

- 40 patents issued, 28 pending